

15 B... Attachment
for... letter

ANNEXURE 1

File No. 27(2)/ 2017-Div-III/NPPA
Government of India
Ministry of Chemicals & Fertilizers
Department of Pharmaceuticals
National Pharmaceutical Pricing Authority

5th/3rd Floor,
YMCA Cultural Centre Building,
1, Jai Singh Road, New Delhi-110001

Date: 15 .12.2017

Office Memorandum

Based on a recent media reports on the treatment cost of a deceased patient diagnosed for dengue at Fortis Memorial Research Institute, Gurgaon, NPPA had directed the concerned hospital to submit the requisite information for investigating the overcharging complaint. The information was submitted by the hospital within the prescribed time limit. NPPA has meanwhile received an application under Right to Information Act for providing details of the information provided by the concerned hospital.

2. In conformity with this Government's commitment to absolute transparency and accountability in governance and honouring the people's right to information, all the details are being placed in public domain through the NPPA's website.

3. Information received from the hospital has been analysed and classified into following categories:

A. Scheduled Formulations, based on National List of Essential Medicines, 2015 (Schedule I of DPCO, 2013) and under price control.

B. Non Scheduled Formulations, (Not under price control and out of Schedule 1 of DPCO, 2013)

C. Consumables, neither under price control and nor under Schedule 1 of DPCO, 2013)

4. NPPA shall be taking necessary follow up action as per existing law and within its jurisdiction.

Anand

(Anand Prakash)
Deputy Director

ANNEXURE-2

गोपनीय: Confidential

मिसिलस. - 8(51)/2017/डी.पी/एनपीपीए-डीवी-II

F. No. 8(51)/2017/DP/NPPA-Div. II

कार्यवाहीस. : 183/51/2017/F

Proceeding No : 183/51/2017/F

Minutes of the 183rd and 51st meeting of Authority under DPCO, 2013 held on 15.12.2017 at 11.00 A.M.

I. The 183rd overall meeting of the Authority, which is the 51st under the DPCO, 2013 was held on 15th December, 2017 at 11.00 AM under the Chairmanship of Shri Bhupendra Singh, Chairman, NPPA. The following members of the NPPA were present:-

- (i) Shri Rakesh Ranjan, Member Secretary
- (ii) Shri Umesh Dongre, Adviser (Cost), Deptt. of Expenditure, Ministry of Finance.
- (iii) Shri Arun Kumar, Adviser, Deptt. of Economic Affairs, Ministry of Finance.
- (iv) Shri A. K. Pradhan, Deputy Drug Controller, Deptt. of Health & Family Welfare (representing DCG(I)).

1.1 The following officers of NPPA also attended the meeting and assisted the Authority in its deliberations:-

- (i) Shri Kalyan Nag, Adviser (Cost)
- (ii) Shri A.P.S. Sawhney, Director (Pricing)
- (iii) Shri Arun Diwan, Dy. Director (O/C)
- (iv) Shri Baljit Singh, Asstt. Director (Pricing)
- (v) Shri Prasenjit Das, Asstt. Director (Pricing)

1.2 Chairman, NPPA welcomed all the members present in the meeting.

II. Agenda items

1. Agenda item no. 1 - Confirmation of Minutes of the 50th Meeting held on 22.11.2017.

1.1 The Authority confirmed the minutes of the overall 182nd and the 50th Meeting held on 22.11.2017 under DPCO, 2013.


2. Agenda item no. 2 - Action Taken Report

2.1 Noted.

2.2 The Authority discussed the matter in details and approved to issue a fresh notification to partially modify the SO. 3727(E) dated 23.11.2017 to give pre-GST retail price and post GST retail price.

3.1 Agenda item no. 3(i) - Fixation of Ceiling Prices under NLEM 2015.

3.1.1 The Authority discussed and approved the ceiling prices of Phenylephrine 5% drops based on institutional data under para 19 of DPCO, 2013 and Anti-D immunoglobulin 150 mcg vial based on para 6 of DPCO, 2013 under monopolistic condition as detailed below:


15/12

S. NO.	UNIQUE NO. AS PER NLEM	NAME OF THE FORMULATION/ COMPOSITIONS	STRENGTH & Dosage Form	Unit for ceiling price	Approved ceiling price under NLEM, 2015 (Rs.)
A. Common Formulations					
1	25.5.3	Phenylephrine	Drops 5%	1 ml	3.38
B. New Formulation					
2	22.2.3	Anti-D immunoglobulin	150 mcg	Each vial	1509.69

4.1 Agenda item no. 4(i) - Price fixation of new drug under Para 5 of DPCO 2013

4.1.1 The Authority examined the retail price fixation of the companies in details. With a view to rationalize the prices of new drug, the Authority decided that wherever, the application has been received by NPPA for any new drug for which NPPA has already notified the price, the same price would be extended to subsequent applicants also. Accordingly, the Authority approved the retail price of 59 new drugs on the basis of retail price already notified after giving excise duty effect for post GST rates as detailed below:

Sl. No.	Name of the Scheduled Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
1.	Ferrous Ascorbate + Folic Acid + Cyanocobalamin + Zinc Sulphate Monohydrate tablet (Autrín - XT)	Each film coated tablet contains: Ferrous Ascorbate eq. to Elemental Iron 100mg, Folic Acid IP 1.5mg, Cyanocobalamin IP 15 mcg, Zinc Sulphate Monohydrate IP eq. to Elemental Zinc 22.5mg	1 Tablet	M/s Tirupati Medicare Limited / M/s Pfizer Limited	3.63
2.	Rosuvastatin + Clopidogrel Capsule (Roseday CV 10)	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin (As granules) 10mg, Clopidogrel Bisulphate IP eq. to Clopidogrel (As a film coated tablet) 75mg	1 Capsule	M/s Aeon Formulation Pvt. Ltd. / M/s USV Private Limited	13.37
3.	Teneligliptin + Metformin tablet (Ten20 M 1000)	Each uncoated bilayered tablets contains: Teneligliptin Hydrobromide hydrate eq. to Teneligliptin 20mg, Metformin HCL 1000mg (as extended release)	1 Tablet	M/s Glenamark Pharmaceuticals Ltd. / M/s Centaur Pharmaceuticals Pvt. Ltd.	10.87
4.	Clobetasol + Clotrimazole + Neomycin Sulphate Cream	Each gm contains: Clobetasol Propionate IP 0.05%w/w, Clotrimazole IP 1.00% w/w, Neomycin Sulphate IP 0.50%w/w	1 GM	M/s Mankind Pharma Ltd./ M/s Pharma Force Lab.	2.92
5.	Moxifloxacin + Cefixime Tablets (Moximac Plus)	Each Coated Sustained Release tablet contains: Moxifloxacin Hydrochloride BP eq. to Moxifloxacin 400mg, Cefixime IP (as trihydrate) eq. to Anhydrous Cefixime 400mg	1 Tablet	M/s Akums Drugs and Pharmaceuticals Ltd. / M/s Macleods Pharmaceuticals Ltd.	33.05
6.	Moxifloxacin + Cefixime Tablets	Each Coated Sustained Release tablet contains: Moxifloxacin	1 Tablet	M/s Akums Drugs and Pharmaceuticals Ltd.	33.05

13/12